Dermatology World May 2012 Supplement : Page 13

Dive in Optimized for effi cacy with minimal irritation 1 1 FOR THE TREATMENT OF ACNE VULGARIS with Atralin ® mean reduction in infl ammatory • 36% lesions at 12 weeks * mean reduction in noninfl ammatory • 41% lesions at 12 weeks * • Low irritation profi le • Moisturizing and hydrating agents 1 † 2-4 * Combined results of two 12-week, prospective, multicenter, randomized, vehicle-controlled studies of patients with mild to moderate acne vulgaris of the face. 1 † The contribution of individual components to effi cacy has not been evaluated. Indication and Important Safety Information: Atralin Gel is indicated for the treatment of acne vulgaris. The most common adverse reaction was mild to moderate irritation of the skin (ie, dry skin, skin burning, erythema, and exfoliative dermatitis), which occurred during the fi rst few weeks of treatment with Atralin Gel. To prevent aggravating the skin, protect it from sun, tanning lights, extreme wind or cold, and harsh skincare products. Use of sunscreen products of at least SPF 15 and protective clothing over treated areas are recommended when exposure cannot be avoided. Atralin Gel should not be used on eczematous or sunburned skin due to potential for severe irritation. References: 1. Data on fi le, CORIA Laboratories. 2. Weindl G, Schaller M, Schäfer-Korting M, Korting HC. Hyaluronic acid in the treatment and prevention of skin diseases: molecular, biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol . 2004;17(5):207-213. 3. Morganti P. Skin hydration. In: Magdassi S, Touitou E, eds. Novel Cosmetic Delivery Systems . New York, NY. Marcel Dekker, Inc; 1999:71-98. 4. Kraft JN, Lynde CW. Moisturizers: what they are and a practical approach to product selection. Skin Therapy Lett . 2005;10(5):1-8. AtralinGel.com Please see brief summary of prescribing information on next page. © 2010 CORIA Laboratories, a division of Valeant Pharmaceuticals North America COR-137791-1210

Atralin for Patients
Using a screen reader? Click Here